Earnings Reports 6 February 2026

July 10, 2026, 6:04 AM EDT. Inspire Medical Systems (INSP) is back under investor pressure after product recalls and index changes, with Wall Street pricing in revenue pressure of 8%. Shares have clawed back 22.06% in the last 30 days but are still off 44.16% for the year and 63% over 12 months, signaling longer-term weakness. Analysts say the stock looks a bit undervalued now, with fair value at $52.17, just above the last close at $51.52. Near-term issues include onboarding delays for the Inspire V system and Medicare billing problems, all clouding the current growth view. Management expects these to resolve by the end of Q3, possibly turning revenue around in 2026. Still, the Street sees reimbursement and adoption risk, so investors weigh the valuation more cautiously now.